Cambendazole is a synthetic benzimidazole anthelmintic agent that inhibits microtubule formation in parasitic nematodes, leading to paralysis and death. It was first synthesized in the 1960s and has been used to treat various parasitic infections in animals, including roundworms, hookworms, and whipworms. Cambendazole is also effective against some protozoan parasites, such as Giardia. Due to its efficacy and broad-spectrum activity, cambendazole is a valuable tool in veterinary medicine and has also been investigated for potential use in human medicine. However, its use in humans is limited due to its potential toxicity and the development of resistance in parasites. Research on cambendazole continues to focus on understanding its mechanism of action, developing new synthetic analogs with improved efficacy and safety profiles, and investigating its potential use against emerging parasitic diseases.'
Cambendazole: A nematocide effective against a variety of gastrointestinal parasites in cattle, sheep, and horses. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 33309 |
| CHEMBL ID | 290578 |
| SCHEMBL ID | 44000 |
| SCHEMBL ID | 23067552 |
| MeSH ID | M0003231 |
| Synonym |
|---|
| isopropyl n-(2-thiazol-4-yl-1h-benzimidazol-5-yl)carbamate |
| mk 905 |
| noviben |
| (methylethyloxy)-n-(2-(1,3-thiazol-4-yl)benzimidazol-5-yl)methanamide |
| 9039-53-6 |
| camdan (tn) |
| cambendazole (usan/inn) |
| D03340 |
| cambendazole [usan:inn:ban] |
| cambendazol [inn-spanish] |
| camdan |
| cambenzole |
| noe [french] |
| brn 0563292 |
| bonlam |
| einecs 247-459-5 |
| isopropyl 2-(4-triazolyl)-5-benzimidazolecarbamate |
| cambendazolum [inn-latin] |
| n-(thiazolyl-4)-2, benzimidazolyl-5, carbamate d'isopropyle [french] |
| equiben |
| cbdz |
| camvet |
| 5-benzimidazolecarbamic acid, 2-(4-thiazolyl)-, isopropyl ester |
| nsc 377071 |
| carbamic acid, (2-(4-thiazolyl)-1h-benzimidazol-5-yl)-, 1-methylethyl ester |
| NCGC00181110-01 |
| novazole |
| nsc-377071 |
| cambendazole |
| nsc377071 |
| 26097-80-3 |
| urokinase |
| CHEMBL290578 |
| propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate |
| NCGC00181110-02 |
| tox21_112724 |
| dtxcid8026852 |
| cas-26097-80-3 |
| dtxsid0046852 , |
| smr003475014 |
| MLS004712049 |
| cambendazol |
| n-(thiazolyl-4)-2, benzimidazolyl-5, carbamate d'isopropyle |
| 079x63s3du , |
| cambendazolum |
| unii-079x63s3du |
| isopropyl 2-(4-thiazolyl)-5-benzimidazolecarbamate |
| cambendazole [green book] |
| cambendazole [usan] |
| cambendazole [who-dd] |
| cambendazole [inn] |
| cambendazole [mart.] |
| cambendazole [mi] |
| SCHEMBL44000 |
| AC-33587 |
| 2-(4-thiazolyl)-5-isopropoxycarbonylaminobenzimidazole |
| isopropyl 2-(1,3-thiazol-4-yl)-1h-benzimidazol-5-ylcarbamate # |
| 5-isopropoxycarbonylamino-2-(4-thiazolyl)benzimidazole |
| carbamic acid, [2-(4-thiazolyl)-1h-benzimidazol-5-yl]-, 1-methylethyl ester |
| QZWHWHNCPFEXLL-UHFFFAOYSA-N |
| 7-[cis-3-(1-azetidinylmethyl)cyclobutyl]-5-[3-(benzyloxy)phenyl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine |
| J-690273 |
| EX-A752 |
| cambendazol; cambendazole; novazole |
| propan-2-yl n-[2-(1,3-thiazol-4-yl)-1h-1,3-benzodiazol-6-yl]carbamate |
| cambendazole, vetranal(tm), analytical standard |
| mfcd00864552 |
| isopropyl 2-(thiazol-4-yl)-1h-benzo[d]imidazol-5-ylcarbamate |
| FT-0700274 |
| BCP07866 |
| DB11380 |
| mk-905 |
| Q15726127 |
| mk 905; nsc 377071; novazole; bonlam; cambendazole; cambenzole |
| carbamic acid, n-[2-(4-thiazolyl)-1h-benzimidazol-6-yl]-, 1-methylethyl ester |
| isopropyl (2-(thiazol-4-yl)-1h-benzo[d]imidazol-5-yl)carbamate |
| AKOS037515510 |
| cambendazole 100 microg/ml in acetonitrile |
| SCHEMBL23067552 |
| BBA09780 |
| HY-107483 |
| CS-0028606 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cambendazole (CBZ) treatments (20 mg/kg) given at 8-week intervals were used for parasite control in a breeding band of ponies (n = 33 to 43) during the period July 1974 to August 1978. " | ( Cambendazole for strongyle control in a pony band: selection of a drug-resistant population of small strongyles and teratologic implications. Drudge, JH; Lyons, ET; Swerczek, TW; Tolliver, SC, 1983) | 3.15 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
The anthelmintic efficacy of cambendazole dosed orally at 20 mg/kg live mass was determined against naturally acquired cestode infestations. In mice infected with metacestodes of Taenia crassiceps, the following compounds were at least partially effective when injected intraperitoneally.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The anthelmintic efficacy of cambendazole dosed orally at 20 mg/kg live mass was determined against naturally acquired cestode infestations in lambs." | ( The efficacy of cambendazole against cestode infestations in lambs. Horak, IG; Snijders, AJ, 1975) | 0.89 |
| "In mice infected with metacestodes of Taenia crassiceps, the following compounds were at least partially effective when injected intraperitoneally at the dosage indicated: cambendazole (500 mg/kg), mebendazole (6." | ( Effect of parenterally injected benzimidazole compounds on Echinococcus multilocularis and Taenia crassiceps metacestodes in laboratory animals. Blair, LS; Campbell, WC; McCracken, RO, 1975) | 0.45 |
| " Thiabendazole at a dosage of 44 mg/kg was tested in 8 foals, oxfendazole at 10 mg/kg was tested in 4 foals, and phenothiazine at 55 mg/kg, cambendazole at 20 mg/kg, and fenbendazole at 5 mg/kg were tested in 1 foal each." | ( Resistance of population-B equine strongyles to thiabendazole, oxfendazole, and phenothiazine (1981 to 1987). Drudge, JH; Lyons, ET; Tolliver, SC, 1991) | 0.48 |
| " However, 6 weeks after dosing the reduction of the strongyle egg output had decreased to an average of 67." | ( Prevalence and control of benzimidazole-resistant small strongyles on German thoroughbred studs. Bauer, C; Bürger, HJ; Janke-Grimm, G; Merkt, JC, 1986) | 0.27 |
| " A dosage of 20 mg/kg showed reduction of mean parasite burdens as follows: Strongylinae greater than 99%; Cyathostominae 94%; immature and adult Oxyuris equi 89 and greater than 99%; Probstmayria vivipara greater than 99% and Habronema muscae 97%." | ( A critical efficacy test of cambendazole in equids: the use of the geometric means to assess efficacy. Louw, JP; Meyer, S; Schröder, J, 1980) | 0.56 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 9.0743 | 0.0072 | 15.7588 | 89.3584 | AID624030 |
| TDP1 protein | Homo sapiens (human) | Potency | 1.0150 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 12.0894 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743042; AID743053; AID743054; AID743063 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 23.9145 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 5.0119 | 0.0054 | 28.0263 | 1,258.9301 | AID1346985 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 9.1800 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743079; AID743080; AID743091 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 6.8131 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 5.9557 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 8.9125 | 0.1000 | 9.1916 | 31.6228 | AID1346983 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 3.7578 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 7.3751 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 15.8369 | 0.0056 | 12.3677 | 36.1254 | AID624044 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 2.6356 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 10.5909 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 10.5909 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID117565 | Compound was administered at 125 p.p.m. in the diet of mice, for percent reduction of Nematospiroides dubius in mice | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Substituted imidazo[2,3-alpha]pyridine-2-carbamate anthelmintics. |
| AID117709 | Compound (250 p.p.m.) was tested for percent reduction of Nematospiroides dubius in mice | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Isomeric phenylthioimidazo[1,2-alpha]pyridines as anthelmintics. |
| AID117562 | Compound (1000 p.p.m.) was tested for percent reduction of Nematospiroides dubius in mice | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Isomeric phenylthioimidazo[1,2-alpha]pyridines as anthelmintics. |
| AID117708 | Compound (125 p.p.m.) was tested for percent reduction of Nematospiroides dubius in mice | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Isomeric phenylthioimidazo[1,2-alpha]pyridines as anthelmintics. |
| AID117693 | Compound was administered at 250 p.p.m. in the diet of mice, for percent reduction of Nematospiroides dubius in mice | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Substituted imidazo[2,3-alpha]pyridine-2-carbamate anthelmintics. |
| AID117694 | Compound was administered at 500 p.p.m. in the diet of mice, for percent reduction of Nematospiroides dubius in mice | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Substituted imidazo[2,3-alpha]pyridine-2-carbamate anthelmintics. |
| AID117710 | Compound (500 p.p.m.) was tested for percent reduction of Nematospiroides dubius in mice | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Isomeric phenylthioimidazo[1,2-alpha]pyridines as anthelmintics. |
| AID117711 | Compound (62.5 p.p.m.) was tested for percent reduction of Nematospiroides dubius in mice | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Isomeric phenylthioimidazo[1,2-alpha]pyridines as anthelmintics. |
| AID117695 | Compound was administered at 62.5 p.p.m. in the diet of mice, for percent reduction of Nematospiroides dubius in mice | 1981 | Journal of medicinal chemistry, Dec, Volume: 24, Issue:12 | Substituted imidazo[2,3-alpha]pyridine-2-carbamate anthelmintics. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 72 (82.76) | 18.7374 |
| 1990's | 9 (10.34) | 18.2507 |
| 2000's | 3 (3.45) | 29.6817 |
| 2010's | 2 (2.30) | 24.3611 |
| 2020's | 1 (1.15) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.15) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 8 (7.69%) | 5.53% |
| Reviews | 3 (2.88%) | 6.00% |
| Case Studies | 2 (1.92%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 91 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||